CLSDClearside Biomedical, Inc.

Nasdaq clearsidebio.com


$ 1.26 $ -0.08 (-5.97 %)    

Thursday, 25-Apr-2024 15:59:54 EDT
QQQ $ 430.17 $ -2.06 (-0.48 %)
DIA $ 380.88 $ -3.52 (-0.92 %)
SPY $ 507.81 $ -1.92 (-0.38 %)
TLT $ 87.78 $ -0.62 (-0.7 %)
GLD $ 215.92 $ 1.28 (0.6 %)
$ 1.26
$ 1.31
$ 0.00 x 0
$ 0.00 x 0
$ 1.26 - $ 1.34
$ 0.65 - $ 2.12
135,399
na
77.88M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-12-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-14-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-11-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-13-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-14-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-16-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-12-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-6-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.

 jmp-securities-reiterates-market-outperform-on-clearside-biomedical-maintains-5-price-target

JMP Securities analyst Jonathan Wolleben reiterates Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and maintain...

 wedbush-maintains-outperform-on-clearside-biomedical-lowers-price-target-to-4

Wedbush analyst Liana Moussatos maintains Clearside Biomedical (NASDAQ:CLSD) with a Outperform and lowers the price target f...

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 clearside-biomedical-q4-2023-adj-eps-008-beats-009-estimate-sales-630m-beat-443m-estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-march-12-2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

 clearside-biomedical-announces-pricing-of-15m-registered-direct-offering-with-institutional-investors-and-an-existing-stockholder-providing-for-the-purchase-and-sale-of-11111111-shares-of-common-stock-and-accompanying-warrant

Clearside Biomedical, Inc. ("Clearside" or the "Company") (NASDAQ:CLSD), a biopharmaceutical company revolution...

 top-5-health-care-stocks-that-may-crash-this-month

As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

 ocular-gene-therapy-regenxbio-data-shows-consistent-preservation-of-visual-acuity-retinal-thickness

Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocula...

 clearside-biomedical-reports-progress-in-odyssey-phase-2b-trial-of-cls-ax-in-wet-amd

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of ...

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-6-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION